(Q35554218)

8 August 2017

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis (English)

1 reference

8 August 2017

0 references

Rudwaleit M

1

1 reference

8 August 2017

Listing J

2

1 reference

8 August 2017

Brandt J

3

1 reference

8 August 2017

Braun J

4

1 reference

8 August 2017

Sieper J

5

1 reference

8 August 2017

language of work or name

English

0 references

publication date

22 March 2004

1 reference

Annals of the Rheumatic Diseases

8 August 2017

1 reference

8 August 2017

63

1 reference

8 August 2017

6

1 reference

8 August 2017

665-670

1 reference

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

8 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755042

Infection complications associated with the use of biologic agents

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755042

Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755042

Predictors of end stage lung disease in systemic sclerosis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755042

Conventional treatments for ankylosing spondylitis.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755042

Ankylosing spondylitis: an overview

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755042

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755042

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755042

A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755042

A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755042

Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755042

Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755042

Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755042

Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety

26 September 2018

1 reference

12 December 2020

Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study

1 reference

12 December 2020

Use of contrast enhanced magnetic resonance imaging to detect spinal inflammation in patients with spondyloarthritides

1 reference

12 December 2020

Magnetic resonance imaging and axial involvement in spondylarthropathies. Delineation of the spinal entheses

1 reference

12 December 2020

The bath ankylosing spondylitis radiology index (BASRI): A new, validated approach to disease assessment

1 reference

12 December 2020

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis

1 reference

12 December 2020

Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients

1 reference

12 December 2020

Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Société de Rhumatologie de l'Ouest

1 reference

12 December 2020

Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis

1 reference

12 December 2020

Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study

1 reference

12 December 2020

Infliximab treatment of severe ankylosing spondylitis: one-year followup

1 reference

12 December 2020

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

1 reference

12 December 2020

Identifiers

DOI

10.1136/ARD.2003.016386

1 reference

8 August 2017

1 reference

8 August 2017

1 reference